Conference Roundup

Maralixibat well tolerated in patients with ALGS in real-world setting

Patients with ALGS treated with maralixibat in a real-world analysis had lower rates of adverse events (AEs) than described in clinical trials, according to data presented at The Liver Meeting of the American Association for the Study of Liver Diseases. Real-world safety data from all patients treated with maralixibat through...